What is Instylla?
Founded in 2017 by Incept LLC and headquartered in Bedford, Massachusetts, Instylla is dedicated to advancing embolization therapy through innovative hydrogel-based solutions. The company's core focus lies in improving patient outcomes and enhancing procedure efficiency for clinicians operating within the complex fields of interventional radiology and oncology. By leveraging its unique material science platform, Instylla addresses significant unmet clinical needs, positioning itself as a transformative force in the medical technology landscape. The company's trajectory reflects a disciplined approach to product development and clinical validation, supported by a robust network of strategic healthcare investors.
How much funding has Instylla raised?
Instylla has raised a total of $85.6M across 5 funding rounds:
Series A
$8.1M
Debt
$350K
Series B
$25.4M
Private Equity
$30M
Stock/Share Issuance
$21.7M
Series A (2017): $8.1M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Series B (2020): $25.4M supported by Incept, Excelestar Ventures LLC, Sparta Group, Ascension Ventures, Amed Ventures, and Catalyst Health Ventures
Private Equity (2023): $30M featuring Excelestar Ventures, Catalyst Health Ventures, Delos Capital, AME Ventures, and Ascension Ventures
Stock/Share Issuance (2025): $21.7M, investors not publicly disclosed
Key Investors in Instylla
Ascension Ventures
A strategic healthcare venture firm that invests on behalf of leading community health systems, focusing on companies that transform the healthcare industry and enhance patient care.
Catalyst Health Ventures
A venture capital firm dedicated to enhancing the health innovation ecosystem by facilitating strategic partnerships and supporting transformative medical technologies.
Excelestar Ventures
A venture capital firm specializing in B2B companies within the tech and medical device sectors, with a strong commitment to supporting diverse leadership teams.
What's next for Instylla?
With this latest major strategic investment, Instylla is well-positioned to accelerate its commercialization efforts and expand the clinical application of its hydrogel technology. The company is expected to prioritize the scaling of its manufacturing capabilities and the broadening of its market reach, ensuring that its embolic products become a standard of care in oncology and vascular interventions. As the firm transitions into this mature growth stage, the focus will likely shift toward long-term clinical efficacy studies and the establishment of deeper partnerships with major health systems, further cementing its role as a leader in the next generation of minimally invasive medical devices.
See full Instylla company page
